Sresan Pharma Under Investigation For Child Deaths Linked To Coldrif Cough Syrup

The Enforcement Directorate (ED) is actively investigating Sresan Pharma in connection with the Coldrif cough syrup case. This investigation follows the tragic deaths of numerous children, primarily under five years old, in Madhya Pradesh and Rajasthan. The ED is conducting searches at seven locations in Chennai linked to the company under the Prevention of Money Laundering Act (PMLA).

Authorities are focusing on financial documents and other evidence to understand the company's operations and regulatory compliance. The raids also target residences of senior officials from the Tamil Nadu drug control office. This step aims to uncover any lapses or misconduct that may have contributed to this tragedy.

Coldrif Cough Syrup's Dangerous Composition

Sresan Pharma, based in Kanchipuram, was licensed by the Tamil Nadu Food and Drug Administration (TNFDA) in 2011. Despite having poor infrastructure and violating national drug safety rules, it operated for over a decade without significant checks. The Central Drugs Standard Control Organisation (CDSCO) revealed that Coldrif syrup was dangerously contaminated with diethylene glycol (DEG), a toxic chemical.

On 9 October, Madhya Pradesh Police arrested G Ranganathan, the owner of Sresan Pharma, following these alarming findings. This arrest marks a critical step in holding those responsible accountable for the severe consequences of their actions.

Political Reactions and Criticisms

K Annamalai, former president of Tamil Nadu BJP, criticised the state government for its regulatory shortcomings. At Madurai airport, he stated that the Chief Minister should be held accountable for these failures. He questioned how drug controllers could identify toxic substances like DEG without proper training.

Annamalai further mentioned that the union government intends to enhance drug safety regulations by testing drugs post-production for harmful content. "There are many stages to drug testing," he noted, "but they are mostly tested during production." He emphasised that post-production checks would help close gaps in India's drug safety regulations.

Investigation Status

In response to these tragic events, authorities continue to investigate both Sresan Pharma's practices and TNFDA's oversight failures. Raids are ongoing as officials scrutinise company records to assess malpractice and determine accountability. This comprehensive investigation aims to prevent such incidents from recurring.

Annamalai highlighted over 300 quality violations related to Coldrif syrup at Sresan Pharma. He criticised Tamil Nadu's drug controllers and inspectors for failing to conduct proper checks. "The Tamil Nadu government is responsible," he insisted, urging them not only to explain but also take responsibility for this oversight.